Effect of Prolectin-M: a (1-6) alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A proof of concept, Open label randomized controlled Trial

MS Composite Interceptive Med Science Laboratories Pvt Ltd CIMED0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Symptomatic and laboratory-confirmed diagnosis of COVID-19.
•2. Age >=18 years and <=45 years, male and non-pregnant female
•3. Identified within 72 hours of testing positive on RT PCR.
•4. Able to give informed consent to stay in institutional care and undergo 3 times collection of throat and nasal swabs over 7-day period; Day 1, Day 3 and Day 5 since randomization

•1.Oxygen saturation at admission <=96%.
•2.High temperature >=1000 F (>=37.50C) not controlled on oral doses of acetaminophen.
•3.Known history of diabetes on oral medications or insulin.
•4.IL-6 levels >= 3times of laboratory reference range and / or significantly elevated levels of CRP, serum ferritin or d-dimer.
•5.Lymphocyte / monocyte ratio <=3 or neutrophil / lymphocyte ratio >=5 or platelet count <=150,000 cells per microliter
•6.On any chronic medications for more than 4 weeks before randomization or active malignancy or having any co-morbidity that increases risk of rapid disease progression.
•7.Previously tested positive and recovered for SarsCov2

发起方

MS Composite Interceptive Med Science Laboratories Pvt Ltd CIMED